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Abstract
Cardiac output is the amount of blood the heart pumps in 1 minute,
and it is dependent on the heart rate, contractility, preload, and
afterload. Understanding of the applicability and practical relevance
of each of these four components is important when interpreting
cardiac output values. In the present article, we use a simple
analogy comparing cardiac output with the speed of a bicycle to
help appreciate better the effects of various disease processes and
interventions on cardiac output and its four components.
Introduction
Cardiac output, expressed in liters/minute, is the amount of
blood the heart pumps in 1 minute. Cardiac output is logically
equal to the product of the stroke volume and the number of
beats per minute (heart rate). Easy enough, one may think,
but the term cardiac in cardiac output is potentially mis-
leading – with clinician’s sometimes assuming that to inter-
pret cardiac output they must focus on the heart. The heart is
just one part of the much larger cardiovascular system,
however, and the amount of blood it pumps is dependent on
both cardiac and extracardiac factors.
Although most clinicians should/will be able to recite the four
determinants of cardiac output – heart rate, contractility,
preload, and afterload – understanding of the applicability
and practical relevance of each of these four components is
all too often less well ingrained. To try to clarify the individual
roles and the combined roles of these four factors in
generating cardiac output, and hence to facilitate our
understanding of the effects of disease processes and
therapies on cardiac output, I use a simple analogy that
equates cardiac output (that is, the amount of blood pumped
by the heart over a period of time) with the speed of a bicycle
at a particular time point (Figure 1).
The analogy and the four determinants of
cardiac output
Heart rate
The heart rate is perhaps the simplest determinant of cardiac
output to visualize: the faster the heart beats, the more blood
can be pumped over a particular period of time. Using our
analogy, the faster the cyclist pedals, the faster the bicycle
will go. But things are not quite so simple! Staying with the
bicycle analogy, it is easy to imagine that if the cyclist pedals
too fast for too long, he/she will get tired and be unable to
maintain the rate of pedaling, so the bicycle will slow. There is
an optimal rate of pedaling: too fast and the cyclist will tire
too quickly and have to slow down; too slow and the bicycle
will not move fast enough to cover the required distance.
Similarly, if the heart rate is too slow, usually easily identified
as part of a severe bradyarrhythmia, or is too fast, then
cardiac output can be impaired. Acute supraventricular or
ventricular tachycardia may also be a cause of low cardiac
output, and even of cardiogenic shock.
Contractility
Clearly, if the cyclist flexes his/her muscles a little and pushes
harder on the pedals, then the bicycle will move faster. This
can be equated to an increased contractility of the heart
muscle, resulting in increased cardiac output. Too little pedal
power, or impaired contractility, will reduce cardiac output;
however, too much effort will result in fatigue, sometimes
leading to a complete collapse, with the need to slow down
substantially or even to stop. This may occur with excessive
inotropic support, resulting in increased mortality rates.
Preload
Preload is the degree of myocardial distension prior to
shortening. As initially demonstrated by Otto Frank and
Ernest Starling, an intrinsic property of myocardial cells is that
the force of their contraction depends on the length to which
they are stretched: the greater the stretch (within certain
limits), the greater the force of contraction. An increase in the
distension of the ventricle will therefore result in an increase
in the force of contraction, which will increase cardiac output.
In our analogy, preload can be compared with a tailwind
allowing the cyclist to move faster without any additional
muscular effort. Of course, unlike our analogy – in which the
speed of the bicycle will continue to increase as the speed of
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eventually be reached at which cardiac output will no longer
increase.
Preload largely depends on the amount of ventricular filling. It
should not, however, be confused with the venous return. In
our analogy, the venous return is like the speed of the bicycle
coming towards us. The amount of blood returning to the
heart in any period of time must be equal to the amount of
blood pumped by the heart in the same period, as there is no
place for storage of blood in the heart. Venous return
therefore equals cardiac output, whereas preload is only one
component of cardiac output.
Afterload
Afterload is the force against which the ventricles must act in
order to eject blood, and is largely dependent on the arterial
blood pressure and vascular tone. By cycling on a large
smooth road rather than a narrow, bumpy one, or on a road
with a gentle downhill slope, the bicycle’s speed can increase
significantly for a given degree of muscular effort. A tired
cyclist is particularly sensitive to these aspects. Similarly,
reducing afterload can increase cardiac output, especially in
conditions where contractility is impaired.
Some clinical applications
Myocardial depression of sepsis
Sepsis is usually associated with a normal or high cardiac
output; yet many studies have shown that myocardial
depression can occur even early in the course of sepsis [1],
so why is cardiac output not reduced? The pathophysiology
of sepsis involves the release of cytokines, some of which are
associated with abnormal calcium handling by the cardiac
myocytes [2], leading to reduced myocardial contraction.
Because of the simultaneous tachycardia and reduced
vascular tone, however, afterload is reduced – and cardiac
output can therefore be maintained or even increased. In
addition, the hyperkinetic state seen in sepsis is typically
preceded by fluid therapy. This situation is akin to the cyclist
being too tired to push on the pedals, but being able to keep
up speed because of a smooth downward sloping road.
Deleterious effects of inotropic therapy
As the long-distance cyclist will know, prolonged strenuous
exercise can lead to high tissue oxygen demands, which can
later result in impaired muscle contraction and poor perfor-
mance. Positive inotropic drugs act by different mechanisms
to increase the contractility of the heart, and as such have
been proposed for use in patients with cardiac failure to
increase myocardial contractility and hence cardiac output.
Indeed, in the short-term, acute phase of heart failure, ino-
tropic drugs can be useful to increase cardiac output. When
considered in light of our analogy, however, it is easy to
appreciate that excessive inotropic stimulation may increase
the myocardial oxygen demand, leading ultimately to myo-
cardial ischemia. Indeed, prolonged stimulation with long-
term inotropic therapy has been shown to increase mortality
rates in patients with chronic heart failure [3-5]. In contrast,
reducing the force of contraction may enable the cyclist to
pedal longer; this may account for some of the beneficial
effects of prolonged β-blockade therapy in the treatment of
heart failure.
Beneficial effects of vasodilating substances
Arterial vasodilator therapy results in significant improvements
in cardiac output in patients with heart failure by reducing
afterload (cycling downhill). Interestingly, this therapeutic
approach has been more successful than inotropic stimula-
tion, and has been shown to reduce mortality rates in this
patient population [6,7]. An obvious limitation is the decrease
in arterial pressure, which may compromise organ perfusion.
Potentially harmful effects of vasopressor agents
In contrast to the beneficial effects of vasodilator drugs, the
administration of strong vasopressors may decrease cardiac
output by increasing afterload, even in individuals with normal
cardiac function. This effect is seen, for example, with
phenylephrine, which has almost pure α-adrenergic effects.
Vasopressin may also decrease cardiac output by increasing
vascular tone [8-10]. Considering our analogy, this effect may
be expected – increasing the slope of the road, or making the
surface too uneven, will eventually force most cyclists to get off
their bicycles and walk, thus reducing their speed considerably!
Even norepinephrine, which has some β-adrenergic proper-
ties, may decrease cardiac output in the absence of a
reduction in vascular tone. The cyclist is pushing a bit harder
on the bicycle’s pedals, but as the road is now going uphill
the bicycle’s speed may decrease considerably. High doses
of norepinephrine have been used as an experimental model
of heart failure [11-13].
Figure 1
Four determinants of cardiac output, using an analogy to the speed of
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Effects of inodilating substances
Some drugs, such as phosphodiesterase inhibitors (milrinone,
enoximone) and levosimendan, exert some inotropic effects in
addition to vasodilating effects. This is analogous to pushing
a bit harder on the bicycle’s pedals at the same time as you
pass the top of a hill and the road starts to go down again;
the greater exertion may lead to fatigue, but the downhill
slope helps to maintain speed. This is why these agents may
increase myocardial oxygen requirements less than other
inotropic drugs.
Effects of fluid administration
Fluid administration takes advantage of the Frank–Starling
relationship to increase stroke volume and cardiac output.
Although an excessive increase in the end-diastolic volume
may increase myocardial oxygen requirements, this inter-
vention is associated with relatively limited consequences, as
compared with catecholamines. Fluid administration is like
adding a tailwind to the cyclist.
Effects of calcium entry blockers on cardiac output
As calcium is essential to myocardial contraction, calcium
entry blockers are expected to decrease the force of contrac-
tion of the myocardium. This is observed in isolated myo-
cardium, but not in living organisms, where the simultaneous
decrease in vascular tone (especially with the dihydropyridine
derivatives) helps to maintain and even increase cardiac
output. The cyclist is tired, but the road is smoother, with a
gentler upward slope!
Conclusion
The interpretation of cardiac output is not as straightforward
as it may seem at first glance. Comparing the complex
relationship of cardiac output and its four components with
the speed of a bicycle and its determinants, however, can
help us to understand some of the complex patho-
physiological alterations in critical illness and to appreciate
better the effects of various interventions on cardiac output.
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